← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleUniversity of Southern Californ…Phase 2

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab)

Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBaylor College of MedicinePhase 1

GINAKIT cells + Etanercept (GINAKIT cells + Etanercept)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleGeneMedicine Co., Ltd.Phase 2

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

Head and Neck Cancer; Malignant Melanoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

GP2013 - A Proposed biosimilar rituximab (GP2013 - A Proposed biosimilar rituximab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 3

adalimumab biosimilar (GP2017, GP2017 (adalimumab biosimilar))

Ankylosing Spondylitis · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSandozPhase 3

adalimumab (Humira, GP2017 Adalimumab)

Plaque Type Psoriasis · Plaque Type Psoriasis

#PlaqueTypePsoriasis#Antibody#Phase3#항체#면역항체+2
효능 ORR 46.5%임상시험 1상태 ACTIVE
AntibodystaleGlenmark Specialty S.A.Phase 1

atezolizumab (Tecentriq, GRC 54276 + Atezolizumab)

Advanced Solid Tumor; Lymphoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleGlenmark Specialty S.A.Phase 1

pembrolizumab (Keytruda, GRC 54276 + Pembrolizumab)

Advanced Solid Tumor; Lymphoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBrightPath BiotherapeuticsPhase 2

pembrolizumab (Keytruda, GRN-1201 + Pembrolizumab)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleQuantumLeap Healthcare Collabor…Phase 2

GSK 5733584 + Dostarlimab (GSK 5733584 + Dostarlimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleSuzhou Kintor Pharmaceutical In…Phase 2

nivolumab (Opdivo, GT90001 and Nivolumab)

Metastatic Hepatocellular Carcinoma; HCC · Metastatic Hepatocellular Carcinoma

#MetastaticHepatocellularCarcinom#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleInsel Gruppe AG, University Hos…Phase 2

durvalumab (Imfinzi, Gemcitabin, Cisplatin and Durvalumab)

Bile Duct Cancer · Bile Duct Cancer

#BileDuctCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleCentre Hospitalier Universitair…Phase 2

durvalumab (Imfinzi, Gemcitabine + Cisplatin + Durvalumab)

Advanced Biliary Tract Carcinoma · Advanced Biliary Tract Carcinoma

#AdvancedBiliaryTractCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleInstitut du Cancer de Montpelli…Phase 2

trastuzumab (Herceptin, Gemcitabine - Trastuzumab - Erlotinib)

Metastatic Pancreatic Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma

#MetastaticPancreaticAdenocarcino#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSeoul National University Hospi…Phase 2

nivolumab (Opdivo, Gemcitabine+ nivolumab)

Recurrent or Metastatic Nasopharyngeal Carcinom · Recurrent or Metastatic Nasopharyngeal C

#RecurrentorMetastaticNasopharyng#Antibody#Phase2#항체#면역항체+2
효능 ORR 69.6%임상시험 1상태 ACTIVE
AntibodystaleRoswell Park Cancer InstitutePhase 2

Gemcitabine, Capecitabine and Bevacizumab (Gemcitabine, Capecitabine and Bevacizumab)

Cholangiocarcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE

47 / 92 페이지

← 이전다음 →